Soluble P selectin in systemic sclerosis: Relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease

Thrombosis Research

Volumn 109, Issue 4, 2003, Pages 203-206

  Blann, A D ^a   Constans, J ^b   Carpentier, P ^c   Renard, M ^d   Satger, B ^c   Guerin V ^d   Boisseau, M R ^d   Neau Cransac, N ^e   Conri, C ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b HÔPITAL SAINT ANDRÉ   (France)

^c CHU La Tronche and University   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e HÔPITAL PELLEGRIN   (France)

Author keywords

Soluble P selectin; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; DNA TOPOISOMERASE; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CENTROMERE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SOLUBILITY; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

EID: 0038174961     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00209-3     Document Type: Article

References (25)

1. Kahaleh M.B., LeRoy E.C. Autoimmunity and vascular involvement in systemic sclerosis. Autoimmunity. 31:1999;195-214.
2. Black C.M. The aetiopathogenesis of systemic sclerosis. J. Int. Med. 234:1993;3-8.
3. Reilly I.A.G., Roy L., Fitzgerald G.A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br. Med. J. 292:1986;1037-1039.
4. Catoggio L.J., Bernstein R.M., Black C.M., Hughes G.R.V., Maddison P.J. Serological markers in progressive systemic sclerosis: clinical correlations. Ann. Rheum. Dis. 42:1983;23-27.
5. Bernstein R.M., Steigerwald J.C., Tan E.M. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin. Exp. Immunol. 48:1982;43-51.
6. Herrick A.L., Illingworth K., Blann A.D., Hay C.R.M., Hollis S., Jayson M.I.V. von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann. Rheum. Dis. 55:1996;122-127.
7. Kallenberg C.G.M., Vellenga E., Wouda A.A., The T.H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J. Rheumatol. 9:1982;878-884.
8. Goodfield M.J., Orchard M.A., Rowell N.R. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br. J. Haematol. 84:1993;675-680.
9. Blann A.D., Lip G.Y.H. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 125:1997;135-138.
10. Ertenli I., Kiras S., Arici M., Haznedaroglu I.C., Calguneri M., Celik I.et al. P selectin as a circulating molecular markers on rheumatoid arthritis with thrombocytosis. J. Rheumatol. 25:1998;1054-1058.
11. Takeda I., Kaise S., Nishimaki T., Kasukawa R. Soluble P selectin in the plasma of patients with connective tissue diseases. Int. Arch. Allergy Immunol. 105:1994;128-134.
12. Frijns R., Fijnheer R., Schiel A., Donders R., Sixma J., Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J. Rheumatol. 28:2001;514-519.
13. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Kreigh T., Medsger T.A.et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15:1988;202-205.
14. Blann A.D., Sheeran T.P., Emery P. Von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br. J. Biomed. Sci. 54:1997;5-9.
15. Salojin K.V., Le Tonqueze M., Saraux A., Nassonov E.L., Dueymes M., Piette J.C.et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am. J. Med. 102:1997;178-185.
16. Stratton R.J., Coghlan J.G., Pearson R.D.et al. Different patterns of endothelial cell activation in renal and pulmonary disease in scleroderma. QJM. 91:1998;561-566.
17. Altman D.G. Practical statistics for medical research. 1991;Chapman & Hall, London.
18. Seibold J.R., Harris J.N. Plasma beta thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J. Rheumatol. 12:1985;99-103.
19. Gruschwitz M.S., Hornstein O.P., von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 38:1995;184-189.
20. Kirk G., McLaren M., Belch J.J.F. Soluble P-selectin assay: importance of correct anticoagulant choice. Platelets. 8:1997;159-162.
21. Jilma B., Eichler H.G., Vondrovec B., Breiteneder H., Kyrle P.A., Kitzweger E.et al. Effects of desmopressin on circulating P-selectin. Br. J. Haematol. 93:1996;432-436.
22. Kawabata K., Nagake Y., Shikata K., Fukada S., Nakazono H., Takahashi M.et al. Soluble P-selectin is released from activated platelets in vivo during haemodialysis. Nephron. 78:1998;148-155.
23. Blann A.D., Faragher E.B., McCollum C.N. Increased soluble P-selectin in ischaemic heart disease: a new marker for the progression of atherosclerosis. Blood Coagul. Fibrinolys. 8:1997;383-390.
24. Ridker P.M., Buring J.E., Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 103:2001;491-495.
25. Hillis G.S., Terregino C., Taggart P., Killian A., Zhao N., Dalsey W.C. Elevated soluble P selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial infarction. Am. Heart J. 143:2002;235-241.